TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04002583

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computer assisted ambulatory electroencephalogram
Description: A portable 16 channel CAA-EEG is used to detect epileptiform abnormalities in a 48 hour ambulatory electroencephalogram (EEG)
Study: NCT02515799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacholiquine
Description: Inhaled Tacholiquine ®1% - 5ml

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled Placebo
Study: NCT03620136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: locoregional analgesia by a block on the adductor channel
Description: The block at the adductor channel will be realized under echo guidance, before the spinal anesthesia, by puncture at the upper 1/3 of the thigh. It will be used echogenic needle adapted to the morphotype of each patient, of varying length from 50mm to 100mm. A single injection of 20mL of ROPIVACAINE 2mg / ml, the efficacy of which should be checked before spinal anesthesia is performed by a cold test.~Knee analgesia will be supplemented by per-operative infiltration of 50mL of ROPIVACAINE 2mg / ml at the posterior capsule, once the surfaces joints prepared to accommodate the prosthesis and by two placebo infiltrations of 50mL each of physiological saline in the medial and lateral ligaments and in the edges of the incision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: locoregional analgesia by periarticular local infiltrations
Description: A placebo injection to the adductor channel of 20 mL of physiological serum will be performed in the pre-induction room before surgery, according to the same procedures as the patients of the ACB group.~During the surgical procedure, patients in the ILA group will receive a total dose of 300mg of ROPIVACAINE 2mg / ml in the form of 3 periarticular injections. The first injection of 50mL of ROPIVACAINE 2mg / ml will be made once the articular surfaces are prepared to receive the prosthesis, at the level of the posterior capsule. The second injection of 50mL of ROPIVACAINE 2mg / ml will be performed once the total knee prosthesis is installed, in the medial and lateral ligaments. Finally, the last injection will also include 50mL of ROPIVACAINE 2mg / ml and will be made in the edges of the incision at the time of closure.
Study: NCT03694769

Intervention type: OTHER
Intervention: Semi-structured interview
Description: One-hour interview with researcher

Intervention type: OTHER
Intervention: Drop attack diary
Description: Diary of any drop attacks experienced within an 8 week period
Study: NCT02151916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental care, AG, MI & fluoride varnish
Description: Dental care during pregnancy, or soon thereafter, will comprise of a screening oral examination, extractions, restorations, scaling and prophylaxis, if needed, and will take as many dental visits as required to achieve a non-diseased mouth. Fluoride varnish application to the teeth of children in the immediate intervention group will occur when children are aged 6 to 10 months (time of tooth eruption), 12 and 18 months, as well as at 24 months. Oral health anticipatory guidance and motivational interviewing for the caregivers/mothers in the immediate intervention group will occur during pregnancy and when the children are aged 6-10 months (time of tooth eruption), 12 and 18 months.

Intervention type: OTHER
Group type: OTHER
Intervention: Delayed intervention
Description: Delayed intervention controlled design; all participants ultimately receive the benefits of the interventions. The intervention group receives the interventions when the mother is pregnant until the child is two years old. The delayed intervention group receives the interventions when the child is two years old until the child is three years old.
Study: NCT00479570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00446687
Description: Single 200mg dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00118638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa - 2.25 mcg/kg
Description: Darbepoetin alfa 2.25 mcg/kg QW dosing/ placebo Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa - 500mcg
Description: Darbepoetin alfa 500mcg Q3W dosing / placebo QW
Study: NCT02397915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF nasal spray
Description: FF as a suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose x 4 doses (total dose 110 mcg) administered via a metered side-actuated nasal spray device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF nasal spray
Description: MF as a suspension for intranasal inhalation with unit dose strength of 50 mcg per dose x 4 doses (total dose 200 mcg) administered via a metered top-actuated nasal spray device.
Study: NCT06189027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDMA
Description: Adjunctive administration of MDMA to assist psychotherapeutic process

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Psychotherapy aimed at assisting with PTSD symptom reduction

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychotherapy
Description: Psychotherapy aimed at assisting with PTSD symptom reduction
Study: NCT04258722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resuscitation Personnel
Description: Type of resuscitation team
Study: NCT01995032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 750 mg metformin and 7.5 g L-citrulline daily p.o.
Study: NCT04800484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Soft
Description: Short heel wedge made of soft foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Soft
Description: Short heel wedge made of soft foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Soft
Description: Short heel wedge made of soft foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Soft
Description: Short heel wedge made of soft foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Soft
Description: Short heel wedge made of soft foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Soft
Description: Short heel wedge made of soft foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Soft
Description: Short heel wedge made of soft foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Soft
Description: Short heel wedge made of soft foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Soft
Description: Short heel wedge made of soft foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Soft
Description: Short heel wedge made of soft foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Soft
Description: Short heel wedge made of soft foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Soft
Description: Short heel wedge made of soft foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Soft
Description: Short heel wedge made of soft foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Soft
Description: Short heel wedge made of soft foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Soft
Description: Short heel wedge made of soft foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Soft
Description: Short heel wedge made of soft foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Soft
Description: Short heel wedge made of soft foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Soft
Description: Short heel wedge made of soft foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Soft
Description: Short heel wedge made of soft foam
Study: NCT02064049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir
Description: The treatment phase will commence in year 2. This is 12 weeks of the pangenotypic sofosbuvir/velpatasvir 400/100mg, coformulated into one tablet daily.
Study: NCT02525484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone 801 mg single oral doses will be given either in the form of tablet or capsules under fed or fasted conditions on Days 1, 4, 7 and 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone 801 mg single oral doses will be given either in the form of tablet or capsules under fed or fasted conditions on Days 1, 4, 7 and 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone 801 mg single oral doses will be given either in the form of tablet or capsules under fed or fasted conditions on Days 1, 4, 7 and 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone 801 mg single oral doses will be given either in the form of tablet or capsules under fed or fasted conditions on Days 1, 4, 7 and 10.
Study: NCT02033629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ce 1 ng/ml
Description: TCI Remifentanil Ce 1 ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ce 2 ng/ml
Description: TCI Remifentanil Ce 2 ng/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ce 3 ng/ml
Description: TCI Remifentanil Ce 3 ng/ml
Study: NCT03162744

Intervention type: BEHAVIORAL
Intervention: Post-suicidal crisis interview
Description: Protective factor exploration during post-suicidal crisis interview
Study: NCT03889340

Intervention type: DEVICE
Intervention: IQool
Description: Subjects will undergo hypothermia therapy with the IQool system
Study: NCT03143153

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Specified dose on specified days
Study: NCT01521923

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol + Methotrexate (MTX)
Description: Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at dosage strength of 200 mg/ml.~On a maintenance dose of 200 mg every 2 Weeks (Q2W) until Week 102. On a maintenance dose of 200 mg every 4 Weeks (Q4W) until Week 102/ Placebo (PBO) 1 syringe every 4 Weeks (Q4W).~CZP and PBO administration to be staggered 2 Weeks apart to maintain blind.~The MTX treatment is to remain between 15-25 mg/week.
Study: NCT04800484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Soft
Description: Short heel wedge made of soft foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Soft
Description: Short heel wedge made of soft foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Soft
Description: Short heel wedge made of soft foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam
Study: NCT01521923

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol + Methotrexate (MTX)
Description: Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at dosage strength of 200 mg/ml.~On a maintenance dose of 200 mg every 2 Weeks (Q2W) until Week 102. On a maintenance dose of 200 mg every 4 Weeks (Q4W) until Week 102/ Placebo (PBO) 1 syringe every 4 Weeks (Q4W).~CZP and PBO administration to be staggered 2 Weeks apart to maintain blind.~The MTX treatment is to remain between 15-25 mg/week.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Methotrexate (MTX)
Description: 1 syringe of Placebo every 2 Weeks and MTX.~The MTX treatment is to remain between 15-25 mg/week.
Study: NCT04103151

Intervention type: DEVICE
Intervention: Single lead ECG
Description: Heart Rate Variability will be monitored using a single lead electrocardiogram

Intervention type: DEVICE
Intervention: Single lead ECG
Description: Heart Rate Variability will be monitored using a single lead electrocardiogram
Study: NCT03625778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 will be administered subcutaneously daily according to the MEDI0382 cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 will be administered subcutaneously daily according to the MEDI0382 cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 will be administered subcutaneously daily according to the MEDI0382 cohorts.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously daily according to the Placebo cohorts.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously daily according to the Placebo cohorts.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously daily according to the Placebo cohorts.
Study: NCT02985918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity NPPV
Description: In the high-intensity NPPV group, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O, typically ranging from 20 to 30 cmH2O (or a tolerated maximum), to obtain a VT 10-15 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of arterial blood gases (ABGs; up to 30 cmH2O) to achieve normocapnia (if possible), or to maximally decrease PaCO2 toward normocapnia if normocapnia can not be achieved. If PaCO2 decreases to less than 35 mmHg, IPAP will be decreased to achieve normocapnia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity NPPV
Description: In the low-intensity NPPV group, as well as during the 6-hour trial of low-intensity NPPV, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT 6-10 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of ABGs (up to 20 cmH2O) to achieve a pH of ≥7.35 and to reduce PaCO2 to a level deemed appropriate by the attending physician.
Study: NCT03053440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BGB-3111
Description: 160 mg PO BID until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 420 mg PO QD until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
Study: NCT03531164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kAYAK ERGOMETER GROUP
Description: Kayak ergometer training for 30 min 5 times a week for 6 weeks. The training includes a warming (pre charge) during 3 minutes, a training (charge) characterised by 3-5 intervals with medium to high intensity during 2-4 minutes and pauses of 1-2 minutes between active phases and 2 minutes of cooling down (post charge) to complete 30 minutes of training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL GROUP
Description: Proprioceptive neurofacilitation exercises focused in trunk control during 30 minutes 5 times a week for 6 weeks.
Study: NCT03782259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapagliflozin
Description: Subjects will either receive 10mg tabs of dapagliflozin or identical looking placebo - inactive medication. Subjects have an equal chance of receiving dapagliflozin or placebo. Which treatment subjects receive is decided at random by a computer (purely by chance, like the tossing of a coin). Neither subjects nor the Study Site personnel will know which treatment subjects are assigned to. The study drug must be taken daily. The subject's other medications will not be changed by the study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02045888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADRCs prepared by investigational Celution Device
Description: ADRCs (low dose and high dose) to be used in investigational treatment will be prepared using the investigational Celution Device which is being investigated under IDE 15363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADRCs prepared by investigational Celution Device
Description: ADRCs (low dose and high dose) to be used in investigational treatment will be prepared using the investigational Celution Device which is being investigated under IDE 15363

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is visually matched solution
Study: NCT04300205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity LED light device
Description: Participant wounds are treated with LED light device for 10 minutes, 4 times over the course of 2 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham LED light device
Description: Participants have the light treatment moved off their wound after masking
Study: NCT01208324

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estrogen patch
Description: 150 subjects will be enrolled in a double blind placebo controlled study where they will be randomized to receive either treatment with 17β-estradiol (Vivelle Dot® 0.10 - 0.15 mg/day) or a look-alike placebo patch for a total of approximately 8 weeks. There will be four fMRI test sequences: two test sequences one week apart prior to estrogen treatment (ET) or placebo treatment (PT), and two sequences one week apart following approximately 6-weeks of double-blind ET or PT. During each test day, all subjects will have their blood drawn at specific time intervals and undergo a battery of cognitive testing.While on the ET or PT treatment, all subjects will be instructed to change the patch every 3.5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amino acids
Description: 31.5 mg of amino acids or 31.5 mg of lactose will be administered to subjects on each of their 4 test days. On 2 of the test days subjects will receive the active pills (amino acids) and on the other 2 test days subjects will receive the placebo pills (lactose).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: placebo
Study: NCT04800484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam
Study: NCT01995032

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02760069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled isopropyl alcohol
Description: Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled isopropyl alcohol
Description: Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral ondansetron
Description: Patients will drink elixir containing 4 mg ondansetron in 5 ml of solution. National Drug Code (NDC) 0054-0064-47.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral ondansetron
Description: Patients will drink elixir containing 4 mg ondansetron in 5 ml of solution. National Drug Code (NDC) 0054-0064-47.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled normal saline
Description: Patients will inhale from normal saline pads as needed for nausea up to q30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral placebo
Description: Subjects will drink solution comprised of 0.25 ml of Oral Sweet Sugar Free NDC 0574-0302-16 with 4.75 ml of sterile water for dilution NDC 0264-2101-00
Study: NCT04800484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Firm
Description: Short heel wedge made of firm foam
Study: NCT01675141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.